Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free Survival in the Phase 3 KEYNOTE-716 Study - Pembro vs. Placebo as Adjuvant Therapy in Stage IIB/IIC Melanoma"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Jason Luke
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Jason Luke
Comments 1
Login to view comments.
Click here to Login